Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open-Label, Dose-Finding Study of BAY 43-9006 (Sorafenib) in High-risk Hepatocellular Cancer Patients After Liver Transplantation

NCT00997022 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT00997022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00997022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open-Label, Dose-Finding Study of BAY 43-9006 (Sorafenib) in High-risk Hepatocellular Cancer Patients After Liver Transplantation
Lead sponsor
Columbia University
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2009
Completion date
May 31, 2015
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular cancer